Last reviewed · How we verify
Xenogeneic Tyrosinase DNA Vaccine
Xenogeneic Tyrosinase DNA Vaccine is a Biologic drug developed by Ichor Medical Systems Incorporated. It is currently in Phase 1 development.
At a glance
| Generic name | Xenogeneic Tyrosinase DNA Vaccine |
|---|---|
| Sponsor | Ichor Medical Systems Incorporated |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Xenogeneic Tyrosinase DNA Vaccine CI brief — competitive landscape report
- Xenogeneic Tyrosinase DNA Vaccine updates RSS · CI watch RSS
- Ichor Medical Systems Incorporated portfolio CI
Frequently asked questions about Xenogeneic Tyrosinase DNA Vaccine
What is Xenogeneic Tyrosinase DNA Vaccine?
Xenogeneic Tyrosinase DNA Vaccine is a Biologic drug developed by Ichor Medical Systems Incorporated.
Who makes Xenogeneic Tyrosinase DNA Vaccine?
Xenogeneic Tyrosinase DNA Vaccine is developed by Ichor Medical Systems Incorporated (see full Ichor Medical Systems Incorporated pipeline at /company/ichor-medical-systems-incorporated).
What development phase is Xenogeneic Tyrosinase DNA Vaccine in?
Xenogeneic Tyrosinase DNA Vaccine is in Phase 1.